Otamixaban - Sanofi
Alternative Names: 0673; FXV 673; RPR 130673; XRP 0673; XRP0673ALatest Information Update: 05 Nov 2023
At a glance
- Originator sanofi-aventis
- Developer Sanofi
- Class Antithrombotics; Benzamidines; Butyric acids; Cyclic N oxides; Esters; Pyridines; Small molecules
- Mechanism of Action Factor Xa inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acute coronary syndromes
Most Recent Events
- 03 Jun 2013 Discontinued - Phase-III for Acute coronary syndromes in Argentina (IV)
- 03 Jun 2013 Discontinued - Phase-III for Acute coronary syndromes in Australia (IV)
- 03 Jun 2013 Discontinued - Phase-III for Acute coronary syndromes in Austria (IV)